Vantage Consulting Group Inc Vertex Pharmaceuticals Inc Transaction History
Vantage Consulting Group Inc
- $61.2 Million
- Q2 2024
A detailed history of Vantage Consulting Group Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Vantage Consulting Group Inc holds 488 shares of VRTX stock, worth $245,195. This represents 0.37% of its overall portfolio holdings.
Number of Shares
488
Previous 576
15.28%
Holding current value
$245,195
Previous $240,000
5.0%
% of portfolio
0.37%
Previous 0.35%
Shares
15 transactions
Others Institutions Holding VRTX
# of Institutions
1,716Shares Held
225MCall Options Held
1.19MPut Options Held
1.56M-
Capital World Investors Los Angeles, CA26.7MShares$13.4 Billion2.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA23MShares$11.5 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.7 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$5.89 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA8.54MShares$4.29 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $129B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...